Limited importance of the dominant-negative effect of TP53 missense mutations

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Stoczynska Fidelus, Ewelina ^a   Szybka, Malgorzata ^a   Piaskowski, Sylwester ^a   Bienkowski, Michal ^a   Hulas Bigoszewska, Krystyna ^a   Banaszczyk, Mateusz ^a   Zawlik, Izabela ^a   Jesionek Kupnicka, Dorota ^a   Kordek, Radzislaw ^a   Liberski, Pawel P ^a   Rieske, Piotr ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Cancer cell lines; Dominant negative effect; Heterozygous mutation; TP53

Indexed keywords

ARTICLE; CANCER CELL CULTURE; CELL CLONING; CONTROLLED STUDY; DOMINANT NEGATIVE EFFECT; FBXW7 GENE; FLUORESCENCE ACTIVATED CELL SORTING; GENE MUTATION; GENE SEQUENCE; GENETIC DATABASE; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MARKER GENE; MISSENSE MUTATION; MUTATIONAL ANALYSIS; N RAS GENE; ONCOGENE; PTEN GENE; SEQUENCE ANALYSIS; SINGLE STRAND CONFORMATION POLYMORPHISM; STR GENE; TP53 GENE; ANIMAL; GENETICS; METABOLISM; MOUSE; NEOPLASM; NUCLEOTIDE SEQUENCE; TUMOR CELL LINE;

PROTEIN P53;

ANIMALS; CELL LINE, TUMOR; DATABASES, GENETIC; DNA MUTATIONAL ANALYSIS; HUMANS; LOSS OF HETEROZYGOSITY; MICE; MUTATION, MISSENSE; NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79958264495     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-243     Document Type: Article

References (33)

1. Roemer K. Mutant p53: gain-of-function oncoproteins and wild-type p53 inactivators. Biol Chem 1999, 380:879-887. 10.1515/BC.1999.108, 10494837.
2. Sigal A, Rotter V. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res 2000, 60:6788-6793.
3. Waldman YY, Tuller T, Sharan R, Ruppin E. TP53 cancerous mutations exhibit selection for translation efficiency. Cancer Res 2009, 69:8807-13. 10.1158/0008-5472.CAN-09-1653, 19887606.
4. Vinyals A, Peinado MA, Gonzalez-Garrigues M, Monzó M, Bonfil RD, Fabra A. Failure of wild-type p53 gene therapy in human cancer cells expressing a mutant p53 protein. Gene Ther 1999, 6:22-33. 10.1038/sj.gt.3300786, 10341872.
5. Cuddihy AR, Jalali F, Coackley C, Bristow RG. WTp53 induction does not override MTp53 chemoresistance and radioresistance due to gain-of-function in lung cancer cells. Mol Cancer Ther 2008, 7:980-92. 10.1158/1535-7163.MCT-07-0471, 18413811.
6. Willis A, Jung EJ, Wakefield T, Chen X. Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes. Oncogene 2004, 23:2330-8. 10.1038/sj.onc.1207396, 14743206.
7. Dearth LR, Qian H, Wang T, Baroni TE, Zeng J, Chen SW, Yi SY, Brachmann RK. Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss of heterozygosity as an important aspect of p53 status in human cancers. Carcinogenesis 2007, 28:289-98.
8. Heyne K, Schmitt K, Mueller D, Armbruester V, Mestres P, Roemer K. Resistance of mitochondrial p53 to dominant inhibition. Mol Cancer 2008, 12:7-54. 2440547, 18547443.
9. Ford JM, Hanawalt PC. Li-Fraumeni syndrome fibroblasts homozygous for p53 mutations are deficient in global DNA repair but exhibit normal transcription-coupled repair and enhanced UV resistance. Proc Natl Acad Sci USA 1995, 92:8876-80. 10.1073/pnas.92.19.8876, 41070, 7568035.
10. Nicholls CD, McLure KG, Shields MA, Lee PW. Biogenesis of p53 involves cotranslational dimerization of monomers and posttranslational dimerization of dimers. Implications on the dominant negative effect. J Biol Chem 2002, 277:12937-45. 10.1074/jbc.M108815200, 11805092.
11. Chan WM, Siu WY, Lau A, Poon RY. How many mutant p53 molecules are needed to inactivate a tetramer?. Mol Cell Biol 2004, 24:3536-3551. 10.1128/MCB.24.8.3536-3551.2004, 381690, 15060172.
12. Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT, Crowley D, Jacks T. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 2004, 119:847-860. 10.1016/j.cell.2004.11.004, 15607980.
13. Zhao S, Guan KL. IDH1 mutant structures reveal a mechanism of dominant inhibition. Cell Res 2010,
14. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-39. 10.1056/NEJMoa040938, 15118073.
15. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, Olivier M. Impact of mutant p53 functional properties on TP53 mutation patterns and tumour phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 2007, 28:622-9. 10.1002/humu.20495, 17311302.
16. Ikediobi ON, Davies H, Bignell G, Edkins S, Stevens C, O'Meara S, Santarius T, Avis T, Barthorpe S, Brackenbury L, et al. Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. Mol Cancer Ther 2006, 5:2606-12. 10.1158/1535-7163.MCT-06-0433, 2705832, 17088437.
17. Forbes S, Clements J, Dawson E, Bamford S, Webb T, Dogan A, Flanagan A, Teague J, Wooster R, Futreal PA, Stratton MR. The Catalogue of Somatic Mutations in Cancer COSMIC 2005. Br J Cancer 2006, 94:318-22. 10.1038/sj.bjc.6602928, 2361125, 16421597.
18. Forbes Simon A, Tang G, Bindal N, Sally B, Elisabeth D, Charlotte C, Kok C, Jia M, Ewing R, Menzies A, Teague JW, Stratton MR, Futreal PA. COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer. Nucleic Acids Res 2010, 38:D652-7. 10.1093/nar/gkp995, 2808858, 19906727.
19. http://p53.free.fr
20. Szybka M, Zawlik I, Kulczycka D, Golanska E, Jesien E, Kupnicka D, Stawski R, Piaskowski S, Bieniek E, Zakrzewska M, Kordek R, Liberski PP, Rieske P. Elimination of wild-type P53 mRNA in glioblastomas showing heterozygous mutations of P53. Br J Cancer 2008, 98:1431-3. 10.1038/sj.bjc.6604258, 2361718, 18349850.
21. Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM, Valentin-Vega YA, Terzian T, Caldwell LC, Strong LC, El-Naggar AK, Lozano G. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 2004, 119:861-72. 10.1016/j.cell.2004.11.006, 15607981.
22. Giaretti W, Rapallo A, Sciutto A, Macciocu B, Geido E, Hermsen MA, Postma C, Baak JP, Williams RA, Meijer GA. Intratumor heterogeneity of k-ras and p53 mutations among human colorectal adenomas containing early cancer. Anal Cell Pathol 2000, 21:49-57.
23. Wu XR. Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer 2005, 5:713-25. 10.1038/nrc1697, 16110317.
24. Tamura G. Genetic and epigenetic alterations of tumor suppressor and tumor-related genes in gastric cancer. Histol Histopathol 2002, 17:323-9.
25. Goranova TE, Ohue M, Kato K. Putative precursor cancer cells in human colorectal cancer tissue. Int J Clin Exp Pathol 2009, 2:154-62. 2584340, 19079650.
26. Barnas C, Martel-Planche G, Furukawa Y, Hollstein M, Montesano R, Hainaut P. Inactivation of the p53 protein in cell lines derived from human esophageal cancers. Int J Cancer 1997, 71:79-87. 10.1002/(SICI)1097-0215(19970328)71:1<79::AID-IJC14>3.0.CO;2-4, 9096669.
27. Boonstra JJ, et al. Mistaken Identity of Widely Used Esophageal Adenocarcinoma Cell Line TE-7. Cancer Res 2007, 67:7996-8001. 10.1158/0008-5472.CAN-07-2064, 17804709.
28. Bhatia K, Goldschmidts W, Gutierrez M, Gaidano G, Dalla-Favera R, Magrath I. Hemi- or homozygosity: a requirement for some but not other p53 mutant proteins to accumulate and exert a pathogenetic effect. FASEB J 1993, 7:951-6.
29. Boyle JM, Spreadborough AR, Greaves MJ, Birch JM, Varley JM, Scott D. Delayed chromosome changes in gamma-irradiated normal and Li-Fraumeni fibroblasts. Radiat Res 2002, 157:158-65. 10.1667/0033-7587(2002)157[0158:DCCIGI]2.0.CO;2, 11835679.
30. Laurent-Puig P, Béroud C, Soussi T. APC gene: database of germline and somatic mutations in human tumors and cell lines. Nucleic Acids Res 1998, 26:269-70. 10.1093/nar/26.1.269, 147178, 9399850.
31. Harbour JW. Overview of RB gene mutations in patients with retinoblastoma. Implications for clinical genetic screening. Ophthalmology 1998, 105:1442-7. 10.1016/S0161-6420(98)98025-3, 9709755.
32. Chen J, Röcken C, Lofton-Day C, Schulz HU, Müller O, Kutzner N, Malfertheiner P, Ebert MP. Molecular analysis of APC promoter methylation and protein expression in colorectal cancer metastasis. Carcinogenesis 2005, 26:37-43.
33. Stirzaker C, Millar DS, Paul CL, Warnecke PM, Harrison J, Vincent PC, Frommer M, Clark SJ. Extensive DNA methylation spanning the Rb promoter in retinoblastoma tumors. Cancer Res 1997, 57:2229-37.